How To Address Challenges In Oncology Drug Containment

By T. Page McAndrew


Drug product containment systems comprising Daikyo Crystal Zenith® cyclic olefin polymer (COP) vials have advantages over those comprising glass vials. When matched with NovaPure® stoppers, container closure integrity (CCI) performance has been quantified for oxygen and carbon dioxide, at temperatures from room temperature through cryogenic temperatures, with excellent system performance. For these reasons, they are an excellent choice for oncology therapies, in particular those based on gene and cell therapies that require cryogenic storage.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development

West Pharmaceutical Services, Inc.